AMENDMENT NO. 1 TO THE NON-DISCLOSURE AGREEMENT by and betweenNon-Disclosure Agreement • December 9th, 2024 • Roche Holdings Inc
This amendment no. 1 to the Non-Disclosure Agreement effective as of 9 March 2021 (“Amendment No. 1”) is effective as of November 19, 2021(the “Amendment No. 1 Effective Date”) by and between
AMENDMENT NO. 2 TO THE NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 9th, 2024 • Roche Holdings Inc
This amendment No. 2 to the Non-Disclosure Agreement (the “Amendment No. 2”) is made and entered into effective as of 10 March, 2023 (the “Amendment No. 2 Effective Date”) by and between
NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • December 9th, 2024 • Roche Holdings Inc
This Non-Disclosure Agreement (“Agreement”), effective March 9, 2021 (“Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with offices at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”) and Poseida Therapeutics, Inc., with offices at 9390 Towne Centre Dr #200, San Diego, CA 92121 (“Company”).
